Lycia targets $228 million IPO to fund food allergy candidate rivaling Xolair
Start here
Lycia, a biotech developing a food allergy candidate, has filed to raise $228 million in an initial public offering. The proceeds are intended to fund clinical data generation for the candidate, which the company positions as a competitor to Xolair, the established antibody therapy for allergic disease. The IPO would give Lycia the capital to advance the program through studies needed to establish its profile against the incumbent. At this point the offering is planned rather than completed, so the final amount raised, the timing of the listing and the resulting clinical data all remain open questions.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- Google NewsLycia aims for $228M IPO to generate data on food allergy rival to Xolair - Fierce Biotech
Lycia plans to raise $228 million in an IPO to generate data on a food allergy candidate and position it as a competitor to Xolair.
Coverage and heat for this story
Reports so far 1·Heat now 6·Peak heat 10 (Oct 20 23:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.